MRK

When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized.

Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cushion that changes the entire income calculus.

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck CEO Rob Davis told CNBC that he expects the company's breakthrough cancer vaccine with Moderna to get faster to make over time. Davis acknowledged that manufacturing the vaccine is a "complex system," but said Merck and Moderna have the process "down to a very tight science.

MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-2029.

The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential Symposia at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain from Oct. 23-27. Additionally, more than 90 additional abstracts across more than 20 tumor types from the company's pipeline and portfolio will be presented throughout the meet.

Jefferies has cut its peak sales forecast for Merck & Co Inc (NYSE:MRK, XETRA:6MK)'s experimental eye treatment remigromig by 60% after detailed trial results raised concerns about its efficacy and safety compared with an established rival. The US pharmaceutical company's drug met the statistical threshold for non-inferiority against Lucentis, a treatment for diabetic macular oedema, but delivered smaller numerical improvements in patients' vision.

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?